With a commitment to improving the prognosis of heart valve disease, Aptus Bioreactors provides novel bioreactor systems and accessories capable of creating and testing living, patient-specific, tissue engineered heart valves. Using the TEHVs, we envision "One Surgery, for Life" where hospital costs, risks, and other burdens associated with heart valve disease are eliminated.